How has been the historical performance of Alembic Pharma?

Answer:The historical performance of Alembic Pharma shows a steady increase in net sales and total operating income over the years, with net sales reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure also rose to 5,663.84 Cr in March 2025, reflecting an increase from 5,295.27 Cr in March 2024. Operating profit (PBDIT) for March 2025 was reported at 1,050.79 Cr, a rise from 961.67 Cr in the previous year, while profit before tax increased to 706.31 Cr from 632.81 Cr. However, profit after tax saw a slight decline to 581.14 Cr in March 2025 from 616.80 Cr in March 2024. The company's total assets grew to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024, indicating a solid asset base. Total liabilities also increased to 7,606.90 Cr, with total debt rising to 1,195.57 Cr. The cash flow from operating activities decreased to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, leading to a net cash outflow of 36.00 Cr.

Breakdown:
Alembic Pharma's financial trajectory demonstrates consistent growth in net sales, which increased from 5,305.79 Cr in March 2022 to 6,672.08 Cr in March 2025. This upward trend in revenue is accompanied by a rise in total operating income, which reached 6,672.08 Cr in March 2025. Despite the increase in total expenditure to 5,663.84 Cr, the operating profit (PBDIT) improved to 1,050.79 Cr, reflecting better operational efficiency. Profit before tax also rose to 706.31 Cr, although profit after tax slightly decreased to 581.14 Cr. The company's total assets expanded to 7,606.90 Cr, while total liabilities increased correspondingly, indicating a growing financial footprint. The cash flow from operating activities, however, saw a decline, resulting in a net cash outflow, which highlights potential liquidity challenges despite the overall growth in sales and assets.